You are here: Industry Insights > Merck

News List

Merck gains NASH candidate from NGM Biopharmaceuticals pharmaceutical-technology
January 08, 2019
Merck has exercised the option to license an investigational product called NGM313 from NGM Biopharmaceuticals under a strategic agreement signed between the companies in 2015.....
Pfizer, Merck to terminate Phase III Bavencio study pharmatimes
January 04, 2019
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio (avelumab), as the data did not support the study's initial hypothesis.
Merck shells out $2.4B for cutting-edge animal tech fiercepharma
January 03, 2019
Bayer may be getting out of the animal health business, but Merck & Co. is plowing ahead—and in a new market to boot. The pharma giant is scooping up Antelliq, a company that specializes in digital ID and tracking
FDA grants breakthrough device designation to Bayer, Merck’s AI for spotting CTEPH fiercebiotech
January 02, 2019
The FDA granted Bayer and Merck & Co. a breakthrough device designation for an artificial intelligence-based pattern recognition software used to spot a rare form of pulmonary hypertension in CT scans......
Merck Provides Update on KEYTRUDA sBLA for KEYNOTE-042 Trial americanpharmaceuticalreview
December 29, 2018
Merck announced the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA.....
Merck, Pfizer Terminate Avelumab Trial of Previously Untreated Advanced Ovarian Cancer americanpharmaceuticalreview
December 27, 2018
Merck and Pfizer have announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab did not support the study's initial hypothesis.....
Merck/Pfizer’s Bavencio flunks second ovarian cancer trial pharmaphorum
December 25, 2018
Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients....
As immuno-oncology heads into 2019, one thing is clear: It’s good to be Merck fiercepharma
December 24, 2018
When 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size.
Merck takes a back seat on CAR-T, handing assets to Intrexon pharmaphorum
December 24, 2018
Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies.
Merck’s Ebola vaccine has 'major impact,' but U.S. should help as outbreak worsens: experts fiercepharma
December 19, 2018
Merck & Co.’s experimental Ebola vaccine rVSV-ZEBOV has been deployed widely in the Democratic Republic of Congo.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page